Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of lurasidone in acutely psychotic adults with schizophrenia
ISRCTN16838597Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Nov 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of lurasidone in schizophrenia (4 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Primary efficacy endpoint. Started Nov 2007; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ISRCTN16838597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16838597.